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Cisplatin is a classic chemotherapeutic agent widely used to treat different types of
cancers including ovarian, head and neck, testicular and uterine cervical carcinomas.
However, cisplatin induces acute kidney injury by directly triggering an excessive
inflammatory response, oxidative stress, and programmed cell death of renal tubular
epithelial cells, all of which lead to high mortality rates in patients. In this study, we
examined the protective effect of protocatechuic aldehyde (PA) in vitro in cisplatin-
treated tubular epithelial cells and in vivo in cisplatin nephropathy. PA is a monomer of
Traditional Chinese Medicine isolated from the root of S. miltiorrhiza (Lamiaceae). Results
show that PA prevented cisplatin-induced decline of renal function and histological
damage, which was confirmed by attenuation of KIM1 in both mRNA and protein
levels. Moreover, PA reduced renal inflammation by suppressing oxidative stress and
programmed cell death in response to cisplatin, which was further evidenced by
in vitro data. Of note, PA suppressed NAPDH oxidases, including Nox2 and Nox4,
in a dosage-dependent manner. Moreover, silencing Nox4, but not Nox2, removed
the inhibitory effect of PA on cisplatin-induced renal injury, indicating that Nox4 may
play a pivotal role in mediating the protective effect of PA in cisplatin-induced acute
kidney injury. Collectively, our data indicate that PA blocks cisplatin-induced acute
kidney injury by suppressing Nox-mediated oxidative stress and renal inflammation
without compromising anti-tumor activity of cisplatin. These findings suggest that PA
and its derivatives may serve as potential protective agents for cancer patients receiving
cisplatin treatment.
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INTRODUCTION
Cisplatin is widely used in the treatment of various cancers
including ovarian, head and neck, testicular and uterine cervical
carcinomas (Pabla and Dong, 2008; Sung et al., 2008). Although
regarded as one of most effective chemotherapeutic agents by
directly interfering with DNA synthesis and inducing apoptosis,
adverse effects such as nephrotoxicity put this promising anti-
cancer agent in a precarious position. In fact, approximately 30%
of patients experience a marked decline in renal function after a
single dose injection of cisplatin (Sung et al., 2008). To this point
it is important to prevent cisplatin-induced acute kidney injury,
which is growing in clinical significance. Although emerging
evidence indicates several pathological mechanisms, including
excessive inflammatory response, oxidative stress, apoptosis and
death of renal tubular epithelial cells, clear therapeutic targets and
effective therapies are still lacking (Sancho-Martinez et al., 2015;
Yang et al., 2016; Zuk and Bonventre, 2016).
Traditional Chinese Medicine (TCM) may be a promising
and novel avenue to effectively treat human diseases with lower
toxicity. Indeed, artemisinin is an impressive example of success
in the war against malaria. Previous studies indicated that
several TCM monomers, such as resveratrol (Kim et al., 2011),
Luteolin (Domitrovic et al., 2013), and Emodin (Liu et al., 2016)
relieved cisplatin-induced acute kidney injury in animal models.
Our recent findings also revealed that 18β-glycyrrhetinic acid
alleviated cisplatin-induced apoptosis of renal tubular epithelial
cells by targeting HDAC2/BMP-7 axis (Ma et al., 2016). However,
the identification of more efficient and low toxic therapeutic
agents needs more research. In our pilot study, we tested 10
potential anti-inflammatory TCM monomers including aloin,
barbaloin, icariin, protocatechuic acid, protocatechuic aldehyde
(PA), puerarin, sodium houttuyfonate, sophoridine, wogonin,
and wogonoside, which have not been investigated in the kidney
field or in cisplatin-treated tubular epithelial cells (data not
shown). Results presented here show that PA, isolated from the
root of S. miltiorrhiza, is one of the most powerful protective
TCM monomers. It significantly suppressed cisplatin-induced
injury of tubular epithelial cells and the inflammatory response.
This was possibly mediated by inhibition of oxidative stress and
programmed cell death. Moreover, the protective role of PA
was further evidenced in vivo in cisplatin nephropathy, where it
prevented decline of renal function and attenuated renal injury.
More importantly, results of MMT assay in three tumor cell
lines demonstrated that treatment of PA didn’t alter the anti-
tumor property of cisplatin. These findings indicate that PA may
be a potential therapeutic agent for preventing cisplatin-induced
acute kidney injury.
RESULTS
PA Ameliorated Cisplatin-Induced Death
in HK2 Cells
We used an MTT assay to analyze the impact of PA on
cell viability in the human tubular epithelial cell line (HK2).
Results show that PA treatment began to reduce cell viability at
concentrations greater than 1 µM (Figure 1A). Moreover, PA
in concentration of 0.25, 0.5, and 1 µM significantly restored
cell viability after cisplatin treatment (20 µM; Figure 1B). Given
these results, we chose 0.25, 0.5, and 1 µM PA for subsequent
experiments. We also determined whether PA limited the anti-
tumor activity of cisplatin in three solid tumor cells lines,
SMCC-7721, BEL-7402, and U87. MTT assay data show that
cisplatin reduced cell viability of hepatic cancer SMCC-7721 cells,
particularly at 48 h, and administration of PA didn’t reduce
the tumor-suppressive effect of cisplatin (Figure 1C). This was
further supported by the findings that PA didn’t protect against
cisplatin-induced tumor cell death in human hepatic cancer line
BEL-7402 and malignant gliomaU87 cell line.
PA Protected against Cisplatin-Induced
Cell Damage and Inflammatory
Response
To assess whether PA reduces kidney damage, we examined
mRNA and protein expression of kidney injury molecule-
1(KIM1). Western blot and real-time PCR results show that
cisplatin upregulated KIM1. This was decreased by PA treatment
in a time-dependent manner in HK-2 cells (Figures 2A,B).
Additionally, real-time PCR and ELISA analysis show that
PA protected against inflammatory response as evidenced by
decreased chemokine monocyte chemotactic protein (MCP-1),
inflammatory cytokine (IL-8), and proinflammatory cytokine
TNF-α expression levels (Figures 2B,C).
PA Inhibited Cisplatin-Induced Cell
Necroptosis and Apoptosis
We tested the protective effects of PA on cell death of HK2 by
flow cytometric analysis of PI/AnnexinV staining. Results show
that PA alleviated cisplatin-induced necroptosis and apoptosis
(Figure 3A). Mechanistically, PA significantly reduced the key
signaling molecules mediating necroptosis, including RIP1, RIP3,
and phosphorylation of downstream MLML in HK2 cells
(Figure 3B). Furthermore, cleaved-caspase-8, cleaved-caspase-
3, cleaved-caspase-12, and phosphorylation of p53 were also
markedly decreased in response to PA treatment (Figure 3B).
PA Suppressed Cisplatin-Induced Injury
In vitro via Blocking Nox-Mediated
Oxidative Stress
A reactive oxygen species (ROS) assay was performed using
DCF fluorescence in HK2 cells to measure the effect of PA on
oxidative stress. Results show that PA largely decreased ROS in
cisplatin-stimulated HK2 cells (Figure 4A). Moreover, results of
DHE staining show that superoxide levels, the reaction product
of Nox enzymes, were suppressed by PA treatment (Figure 4B).
We know that apocynin or PA treatment decreases cisplatin-
induced damage of tubular epithelial cells. Interestingly, we found
that after blocking Nox enzymes with apocynin, PA failed to
further reduce the renal damage (Figure 4C). This indicates a
role for the Nox family in mediating the protective effect of PA.
Therefore, we analyzed the main members of the Nox family in
kidney, including Nox2 and Nox4. Western blot results show that
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FIGURE 1 | Effect of protocatechuic aldehyde (PA) on cell viability with or without cisplatin treatment. (A) Effect of different concentrations of PA on
viability of HK2 cells by MTT assay. (B) PA restored cell viability in cisplatin-treated HK2 cells (MTT assay). (C) Effect of PA on anti-cancer efficacy of cisplatin. Data
represent the mean ± SEM for at least 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the control. #p < 0.05, ##p < 0.01,
###p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde.
PA treatment reduced cisplatin-induced Nox2 and Nox4 protein
expression in a dose-dependent manner (Figures 4D,F). This was
further supported by real-time PCR data showing reduced Nox2
mRNA and Nox4 mRNA (Figures 4E,G).
PA Attenuated Cisplatin-Induced Injury
through Nox4-Dependent Mechanisms
We determined whether Nox2 and Nox4 are important targets
for PA in mediating its protective effects. We found that
Nox2 and Nox4 were largely suppressed when shRNA plasmids
were transfected into cells (Figures 5A,B). Western blot results
show that PA further suppressed KIM1 levels in absence of
Nox2. But, PA failed to further attenuate renal tubular cell
damage when Nox4 was disrupted (Figure 5C). This indicates
an essential role for Nox4 in mediating protective effects
of PA.
PA Attenuated Cisplatin-Induced
Necrosis, Inflammation, and ROS
through Nox4-Dependent Mechanisms
We analyzed the role of PA on the Nox4 pathway in more
detail in vitro. We found that PA failed to reduce cleaved-
caspase-3 levels in Nox4 knockdown HK2 cells (Figure 6A).
Consistently, when Nox4 was silenced, PA didn’t further suppress
the production of inflammatory cytokines (Figure 6B). This
indicates that PA protects against cisplatin-treated tubular
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FIGURE 2 | Protocatechuic aldehyde reduced cisplatin-induced kidney injury molecule-1 (KIM1) level and inflammatory response in HK2 cells.
(A) Western blot analysis and quantitative data of KIM-1 in HK2 cells. (B) Real-time PCR in HK2 cells. Results demonstrate that treatment of PA largely reduced
cisplatin-induced mRNA levels of KIM1, TNF-α, MCP-1, and IL-8. (C) ELISA in HK2 cells. Results indicate that treatment with PA significantly reduced
cisplatin-upregulated protein levels of IL-8 and MCP-1 in HK2 cells. Data represent the mean ± SEM for 3–4 independent experiments.∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 compared to the control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde.
epithelial cells in a Nox-dependent manner. These results were
further confirmed by detecting MDA level, which showed that
ROS levels were consistent (Figure 6C).
PA Inhibited Cisplatin-Induced Acute
Kidney Injury in Mice
The protective effect of PA was also evaluated in vivo in
cisplatin nephropathy. Results of periodic acid-Schiff (PAS)
staining revealed that administration of PA in concentrations of
0.45, 0.9, and 1.8 mg/kg reduced tubular necrosis, dilation, and
cast formation compared with model groups (Figure 7A). The
therapeutic effects of PA were further confirmed by detection
of renal function, including serum creatinine and blood urea
nitrogen. Results show that PA largely prevented the decline of
renal function in a dose-dependent manner (Figures 7B,C).
PA Significantly Reduced
Cisplatin-Induced Tubular Injury and
Inflammation Response in Mice
Western blot and quantitative data show that KIM1, a
key marker for tubular injury, was significantly elevated by
cisplatin but reduced by PA treatment in a dose-dependent
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FIGURE 3 | Protocatechuic aldehyde inhibited cisplatin-induced cell necroptosis and apoptosis in HK2 cells. (A) Flow cytometry of PI/AnnexinV. Results
of flow cytometry demonstrate that PA inhibited cisplatin-induced cell necrosis and apoptosis in HK2 cells; (B) Western blot analysis and quantitative data of RIP1,
RIP3, p-MLKL in cisplatin-treated HK2. Results show that administration of PA substantially blocked activation of RIP1/RIP3/MLKL axis in cisplatin-stimulated HK2
cells; In addition, results of Western blot and quantitative data demonstrate that treatment of PA gently decreased cisplatin-induced cleavage of caspases and
phosphorylation of p53 in HK2 cells; Data represent the mean ± SEM for 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the
control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde.
manner (Figure 8A). This was further evidenced by results
from IHC and real-time PCR (Figures 8C,E). PA treatment
also suppressed the increased level of Neutrophil gelatinase-
associated lipocalin (NGAL), another kidney injury marker,
in urine in cisplatin nephropathy (Figure 8B). Additionally,
results from IHC show that PA reduced TNF-α positive signals
in injured kidney. This was consistent with real-time PCR
results showing reduced mRNA levels of proinflammatory
cytokines and chemokines including TNF-α, IL-6, and MCP-1
(Figures 8D,E).
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FIGURE 4 | Protocatechuic aldehyde inhibited cisplatin-induced cell oxidative stress in HK2 cells by suppressing Nox signaling. (A) DCF Assay of
Reactive Oxygen Species. Results of ROS assay demonstrate that PA inhibited cisplatin-induced cell oxidative stress in HK2 cells; (B) DHE staining of intracellular
ROS levels. PA attenuates cisplatin-induced ROS generation. (C) Role of Nox enzymes in the effect of PA on cisplatin-treated HK2 cells. (D,F) Western blot analysis
and quantitative data of Nox2 and Nox4 in cisplatin-treated HK2 cells. Results show that administration of PA substantially suppressed protein levels of both Nox2
and Nox4 in cisplatin-stimulated HK2 cells. (E,G) Real-time PCR in HK2 cells. Results demonstrate that treatment of PA largely reduced cisplatin-induced mRNA
levels of Nox2 and Nox4; Data represent the mean ± SEM for 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the control.
#p < 0.05, ##p < 0.01, ###p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde; APO, Apocynin.
Frontiers in Pharmacology | www.frontiersin.org 6 December 2016 | Volume 7 | Article 479
fphar-07-00479 December 3, 2016 Time: 13:59 # 7
Gao et al. PA Attenuates Acute Kidney Injury
FIGURE 5 | Protocatechuic aldehyde failed to further reduce cisplatin-induced cell injury in Nox4 knockdown, instead of Nox2 knockdown in HK2
cells. (A,B) Identification of Nox2 and Nox4 knockdown in HK2 cells; Results show that Nox2 and Nox4 were downregulated by transfection of Nox2 siRNA and
Nox4 ShRNA plasmid, respectively. (C) Western blot analysis and quantitative data of KIM1 in Nox2 and Nox4 knockdown HK2 cells treated with PA. Data represent
the mean ± SEM for 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared
to Nox4 EV group. $$p < 0.01, $$$p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde; EV, empty vector; KD, knockdown.
PA Protected against Cisplatin
Nephropathy by Attenuating Oxidative
Stress
We then investigated the underlying mechanisms by which PA
improves renal function and limits kidney injury. We found
that MDA levels were significantly increased in kidneys of
cisplatin-injected mice. But, PA reduced the upregulation of
MDA levels in a dose-dependent manner (Figures 9A,B). This
is consistent with the finding that PA restored the cisplatin-
suppressed level of GSH, an antioxidant index. This indicates
that PA substantially decreased cisplatin-induced production of
ROS. Moreover, Western blot and quantitative data show that
PA reduced protein levels of Nox2 and Nox4 in a dosage-
dependent manner in cisplatin nephropathy. This was further
confirmed by immunohistochemistry that revealed that Nox4
was downregulated in cisplatin-injured kidney treated with PA
(Figures 9C,D). Additionally, the function of Nox4 was detected
in vivo. Results of PAS staining indicate that lentivirus-mediated
knockdown of Nox4 significantly attenuated cisplatin-induced
kidney damage (Figure 9E). This demonstrates it may be a critical
target to mediate protective effects of PA.
PA Protected against Cisplatin
Nephropathy by Attenuating Cell Death
Our results show that PA suppressed activation of the
RIP1/RIP3/MLKL axis, which is regarded as the key pathway
mediating necroptosis. We found PA also decreased levels of
cleaved-caspase-3 in cisplatin nephropathy (Figure 10).
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FIGURE 6 | Protocatechuic aldehyde failed to further reduce cisplatin-induced cell apoptosis, inflammatory response, and oxidative stress in Nox4
disrupted HK2 cells. (A) Western blot analysis and quantitative data of cleaved-caspase-3. (B) Real-time PCR analysis of inflammatory response in Nox4 disrupted
HK2 cells. Results show that when Nox4 was disrupted, PA failed to further decrease mRNA levels of KIM1, MCP-1, TNF-α, and IL-8. (C) Malondialdehyde (MDA)
levels in HK2 cells. Results indicate that when Nox4 was knocked down, PA failed to further decrease the MDA levels in cisplatin-stimulated HK2 cells. Data
represent the mean ± SEM for 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the control. #p < 0.05, ##p < 0.01, ###p < 0.001
compared to Nox4 EV group. $p < 0.05, $$p < 0.01, $$$p < 0.001 compared to cisplatin-treated group. Cis, cisplatin; PA, protocatechuic aldehyde; EV, empty
vector; KD, knockdown.
MATERIALS AND METHODS
Murine Model of Cisplatin-Induced AKI
Mice were obtained from Laboratory Animal Center of
Anhui province. All animal procedures were approved by
the Institutional Animal Experimentation Ethics Committee
of Anhui Medical University. Cisplatin with a single dose
at 20 mg/kg was injected intraperitoneally in 8-week-old
male mice and their littermates injected with saline were
set as normal control. Protocatechuic aldehyde (Dalian
Meilun Biotech Co. Ltd.), concentrations of 0.45, 0.9,
and 1.8 mg/kg, were given via intraperitoneal injection
6 h before cisplatin treatment and injected daily. Mice
were sacrificed under anesthesia (10% chloralic hydras by
intraperitoneal injection) 3 days after cisplatin injection.
Samples of kidney tissues and blood were harvested for further
analysis, including BUN (Nanjing Jiancheng Bioengineering
Institute) and creatinine, paraffin embedding (Nanjing Jiancheng
Bioengineering Institute) and molecular analysis. Paraffin
sections (3–5 mm) were stained with Periodic acid Schiff (PAS)
Staining kit (Fuzhou Maixin Biotech. Co., Ltd.) and analyzed via
immunohistochemistry.
Reagents and Materials
Antibodies RIP1, RIP3, KIM-1, Nox2, Nox4, TNF-α, and
β-actin were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); Rabbit anti-P-MLKL and Anti-cleaved-
caspase-3, cleaved-caspase-12 were obtained from Cell Signaling
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FIGURE 7 | Protocatechuic aldehyde prevented cisplatin-induced renal injury and decline of renal function in vivo. (A) PAS staining and score. Results of
PAS staining and score of severity indicate that treatment of a set concentrations of PA alleviated tubular necrosis, tubular dilation, and cast formation in cisplatin
nephropathy; (B) Serum Creatinine; (C) BUN. Results of serum creatinine and BUN show that treatment of PA restored renal function in cisplatin nephropathy. Data
represent the mean ± SEM for 6–8 mice. ∗∗p < 0.01, ∗∗∗p < 0.001 compared to control. ##p < 0.01, ###p < 0.001 compared to model. Cis, cisplatin; PA,
protocatechuic aldehyde.
Technology (CST, Danvers, MA, USA). Lipofectamine 3000
was purchased from Science Biotechnology (Invitrogen, Beijing,
China). Protein Assay Kit was purchased from Beyotime Institute
of Biotechnology (Jiangsu, China). Cell Malondialdehyde (MDA)
assay kit (Colorimetric method), reduced glutathione (GSH)
assay kit, creatinine (Cr) Assay kit (sarcosine oxidase) and
urea (BUN) assay kit were obtained from Nanjing Jiancheng
Bioengineering Institute(Nanjing, China). Reactive Oxygen
Species Assay (DCF Assay) Kit and Dihydroethidium (DHE)
were purchased from Beyotime Institute of Biotechnology
(Jiangsu, China). ITC AnnexinV/propidiuiodide was purchased
from Bestbio (Shanghai, China). Mouse NGAL ELISA kit was
purchased from CUSABIO (Wuhan, China).
Cell Culture
Solid tumor cell lines (SMCC-7721, BEL-7402, and U87), kidney
tubular epithelial cells of human (HK2), and Nox2, Nox4
knockdown HK2 cells were cultured in 5% FBS-containing
HyCloneTM DMEM/F12 medium at 37◦C in humidified 5%
CO2. After overnight starving in DMEM/F12 medium containing
0.5% FBS, HK2 cells were pretreated with PA (Meilun Biology
Technology, Dalian, China) for 6 h before being exposed
to cisplatin (20 µM). Twenty-four hour later, the cells were
harvested for cell viability, the indexes of kidney injury, oxidative
stress, programmed cell death, and inflammatory response such
as KIM1, Nox2, Nox4, cleaved-caspase-3, 8, and 12, p-p53, p53,
RIP1, RIP3, phospho-MLKL, TNF-α, and MCP-1 using Western
blot analysis, real-time PCR or other methods. Three to four
in vitro experiments were performed independently.
Cell Viability Assay
Cell viability is determined by MTT assay, according to a purple
formazan product produced by mitochondrial dehydrogenase of
viable cells. Human HK2 cells were grown in 96-well plates with
treatments by a set of concentrations of PA (arranged from 0.25
to 8 µM). After 12 h, the cells were exposed to cisplatin (20 µM)
for 24 h in incubator. They were harvested after addition of
5 mg/ml MTT solution to each well for 4 h. Optical density (OD)
was determined in microplate reader (Multiskan MK3, Thermo,
USA) at 492 nm wavelength.
RNA Extraction and Real-Time PCR
Total RNA was isolated using the RNeasy Isolation Kit
(Qiagen, Valencia, CA, USA) according to the manufacturer’s
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FIGURE 8 | Protocatechuic aldehyde attenuated cisplatin-induced renal injury and inflammation in vivo. (A) Western blot analysis and quantitative data of
KIM1. Results indicate that treatment of PA in a set of concentrations substantially inhibited cisplatin-induced KIM1 in protein levels. (B) ELISA of urinary neutrophil
gelatinase-associated lipocalin (NGAL). PA treatment also suppressed the increased level of urinary NGAL in cisplatin nephropathy. (C) Immunohistochemistry of
KIM1. IHC result and quantitative data indicate that treatment of PA reduced the percentage of KIM1+ cells in injured kidney; (D) Immunohistochemistry of TNF-α.
IHC result and quantitative data indicate that treatment of PA reduced the percentage of TNF-α+ cells in injured kidney; (E) Real-time PCR of inflammation indexes.
Real-time PCR demonstrate that treatment of PA largely blocked upregulated mRNA levels of KIM1, MCP-1, TNF-α, and IL-6 in cisplatin-injured kidney. Data
represent the mean ± SEM for 6–8 mice. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to model. Cis,
cisplatin; PA, protocatechuic aldehyde.
instructions (Li et al., 2012). The RNA concentration
was detected by a NanoDrop 2000 Spectrophotometer
(Thermo Scientific, USA). RNA, nuclease-free water and
RealMasterMix (Bio-Rad, Hercules, CA, USA) were used
for cDNA synthesis. Real-time PCR was performed in
a total volume of 9 µl, including 2 µl cDNA solution,
4 µlBio-Rad iQ SYBR Green supermix with Opticon 2
(Bio-Rad, Hercules, CA, USA), 2.4 µl nuclease-free water,
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FIGURE 9 | Protocatechuic aldehyde prevented Nox4-mediated oxidative stress in cisplatin nephropathy. (A) The changes of MDA levels in vivo. (B) The
changes of glutathione (GSH) levels in vivo. Results of the MDA activities and GSH activities show that treatment of PA suppressed renal oxidative stress in cisplatin
nephropathy. (C) Western blot analysis and quantitative data of Nox2 and Nox4 in cisplatin nephropathy. Results show that treatment of PA in a set of concentrations
significantly reduced the protein level of Nox2 and Nox4. (D) Immunohistochemistry of Nox4. IHC result and quantitative data indicate that treatment of PA reduced
the percentage of Nox4+ cells in injured kidney. (E) PAS staining of Nox4 knockdown kidney. PAS staining and score show that lentivirus-mediated knockdown of
Nox4 prevented cisplatin-induced kidney damage. Data represent the mean ± SEM for 6–8 mice. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to control.
#p < 0.05, ##p < 0.01, ###p < 0.001 compared to model. Cis, cisplatin; PA, protocatechuic aldehyde.
Frontiers in Pharmacology | www.frontiersin.org 11 December 2016 | Volume 7 | Article 479
fphar-07-00479 December 3, 2016 Time: 13:59 # 12
Gao et al. PA Attenuates Acute Kidney Injury
FIGURE 10 | Protocatechuic aldehyde prevented necrosis and apoptosis in cisplatin nephropathy. Western blot analysis and quantitative data of RIP1,
RIP3, p-MLKL, and cleaved-caspase-3. Data represent the mean ± SEM for 6–8 mice. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to control. #p < 0.05,
##p < 0.01, ###p < 0.001 compared to model. Cis, cisplatin; PA, protocatechuic aldehyde.
FIGURE 11 | Therapeutic effects of PA on cisplatin-induced renal
injury. PA treatment attenuates cisplatin-induced renal injury both in vivo and
in vitro through Nox4-correlated mechanisms.
and 0.6 µl each primer. The sequences of primers are as
follows:
Human IL-8, forward 5′-AGGACAAGAGCCAGGAAGAA-3′,
reverse 5′- ACTGCACCTTCACACAGAGC-3′;
Human TNF-α, forward 5′-CCCAGGGACCTCTCTCTAATCA-3′,
reverse 5′- GCTACAGGCTTGTCACTCGG-3′;
Human KIM-1, forward 5′-CTGCAGGGAGCAATAAGGAG-3′,
reverse 5′-TCCAAAGGCCATCTGAAGAC-3′;
Human Nox4, forward 5′-GGATCACAGAAGGTCCCTAGCAG-3′,
reverse 5′-GCGGCTACATGCACACCTGAGAA-3′;
Human Nox2, forward 5′–3′TTCCAGTGCGTGTTGCTCGAC,
reverse 5′–3′GATGGCGGTGTGCAGTGCTAT;
Human β-actin, forward 5′-CGCCGCCAGCTCACCATG-3′,
reverse 5′-CACGATGGAGGGGAAGACGG-3′;
Mouse IL-6, forward 5′-GAGGATACCACTCCCAACAGACC-3′,
reverse 5′-AAGTGCATCATCGTTGTTCATACA-3′;
Mouse TNF-α, forward 5′- CATCTTCTCAAAATTCGAGTGACAA-3′,
reverse 5′-TGGGAGTAGACAAGGTACAACCC-3′;
Mouse MCP-1, forward 5′- CTTCTGGGCCTGCTGTTCA-3′,
reverse 5′-CCAGCCTACTCATTGGGATCA-3′;
Mouse KIM-1, forward 5′-CAGGGAAGCCGCAGAAAA-3′,
reverse 5′-GAGACACGGAAGGCAACCAC-3′;
Mouse β-actin, forward 5′- CATTGCTGACAGGATGCAGAA-3′,
reverse 5′-ATGGTGCTAGGAGCCAGAGC-3′
Assays were run over 40 cycles with the following conditions:
denaturation at 95◦C for 20 s, annealing at 58◦C for 20 s, and
elongation at 72◦C for 20 s. β-actin was used to normalize the
expression values of the other genes.
Western Blot Analysis
Protein was isolated from pulverized tissue or cells from 6-
well plates in ice-cold RIPA-Buffer (Beyotime, Jiangsu, China).
BCA protein quantitative kit (Beyotime, Jiangsu, China) was
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used to evaluate the protein concentration. For Western blots,
total protein were loaded in 10% SDS-PAGE and transferred
onto nitrocellulose membranes. After blocking, membranes
were incubated with rabbit anti-Nox2, Nox4, anti-KIM-1, anti-
RIP1, anti-RIP3, anti-P-MLKL, anti-cleaved-caspase-3 antibody,
anti-cleaved-caspase-8, anti-cleaved-caspase-12, and mouse anti-
β-actin antibody for 18 h at 4◦C, then incubated with IRDye 800-
conjugated secondary antibody for 1.5 h at room temperature
(1:10000, Rockland immunochemicals, Gilbertsville, PA, USA).
Images were detected by Li-Cor/Odyssey infrared image system
(LI-COR Biosciences, Lincoln, NE, USA) and quantified using
the Image J software (NIH, Bethesda, MD, USA).
Flow Cytometry
The extent of programmed cell death was detected by flow
cytometry (BD FACSVerse, USA) using AV-FITC/PI apoptosis
detection kit (Bestbio, Shanghai, China). Briefly, HK2 cells were
harvested and washed twice with PBS after incubation in cell
culture bottle with/without cisplatin and PA for 24 h. The cells
were centrifuged at 1500 rpm/min for 5 min and stained with
5 µL Annexin V-FITC and 10 µL PI in the dark, followed by flow
cytometry and quantified using FlowJo 7.6 software.
Determination of MDA and GSH
The levels of MDA and GSH in cell or in mouse tissues were
measured with a commercial kit (Jiancheng Co., Nanjing, China)
according to the manufacturer’s instructions. Thiobarbituric acid
reacts with MDA, degradation product of lipid peroxidation
in, to generate red compound which has maximum absorbance
at 532 nm. This assay is commonly called thiobarbituric acid
reactive substances assay (TBARS assay). Homogenate was
centrifuged at 4000 rpm/min (10 min) after incubation with
TBA reagent for 40 min at 100◦C. Supernatant was measured
at 530 nm. 5,5-dithiobis-2-nitrobenzoic acid (DTNB) reacts with
sulfhydryl compounds to generate a yellow compound, whose
absorption peaks at 405 nm. GSH concentration was determined
based on the absorbance of yellow compound. The homogenate
was obtained and centrifuged at 3500 rpm/min for 10 min.
The supernatant was reacted with DTNB and generated yellow-
colored complex, which was measured at 405 nm.
DCF Assay
DCF, the oxidation product of 2,7-dichlorodihydro-fluorescein
diacetate, is a marker of cellular oxidation. Cisplatin-induced the
generation of ROS as revealed by increased 2,7-dichlorodihydro-
fluorescein, which was measured by fluorescence microscopy
with excitation of 488 nm and emission of 525 nm after cells
were incubated with DCF (10 µL/L) for 20 min at 37◦C in no
FBS-containing DMEM/F12 medium.
DHE Staining
The oxidation of DHE, ethidium bound to DNA and fluoresced
red, was used to estimate intracellular ROS levels. Cells were
incubated with 5 µM freshly prepared DHE solution (Beyotime,
Jiangsu, China) for 30 min at 37◦C and then measured under
fluorescence microscopy.
Knockdown of Nox2 and Nox4 in HK2
Cells
Nox2 and Nox4 were silenced by transfection with sequence-
specific or non-targeting siRNA (GenePharm, Shanghai,
China)/shRNA (GeneChem Co. Ltd., Shanghai, China) using
LipofectamineTM 2000 reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Briefly, for each
well of a 6-well plate, 5 µl siRNA/shRNA and 5 µl lipofectamine
2000 were diluted in 200 µl Opti-DMEM separately, and
incubated for 5 min at room temperature in the dark. The diluted
siRNA/shRNA was combined with the diluted Lipofectamine
2000 and incubated for 20 min at room temperature. Finally, the
mixture with 100 ml Opti-DMEM was applied to the cells. After
incubation for 12 h, the medium was replaced with fresh DMEM
supplemented with 5% FBS. Cells with Nox4 shRNA screened by
puromycin were cultured in incubator at 37◦C. The transfection
efficiency was then evaluated using Western blotting.
Renal Histology and
Immunohistochemistry
Renal tissues were fixed in 4% PFA immediately. After
dehydration, samples were embedded in paraffin. According
to the manufacturer’s instruction, PAS staining was performed
in Paraffin sections (3–5 µm) to assess the degree of
tubulointerstitial damage and examined by light microscope
(Olympus, Japan) at 200 × magnification. On PAS-stained
kidney sections (n = 6–8), kidney damage in the cortical
proximal was scored as the approximate extent of tubules
that displayed tubular necrosis, cast formation, and tubular
dilation as follows: 0 = normal; 1 = 10%; 2 = 10–25%;
3 = 26–50%; 4 = 51–75%; 5 = 75–95%; 6 = more than
96%. Immunohistochemistry was performed in paraffin sections
using a microwave-based antigen retrieval technique (Li et al.,
2012). Sections were incubated with rabbit anti-Nox4, anti-
KIM-1, anti-TNF-α, and rabbit anti-F4/80 antibody overnight
at 4◦C. After incubation in secondary antibody and chromagen
liquid DAB (3,30-diaminobenzidine tetrahydrochloride), the
slides were counterstained with hematoxylin. The results were
analyzed by Image Analysis System (AxioVision 4, Carl Zeiss,
Jena, Germany).
Statistical Analyses
Data are expressed as the mean ± SEM. Statistical significance
was analyzed by two-tailed unpaired t-test or one-way analysis
of variance (ANOVA), followed by Tukey post hoc tests using
GraphPad Prism 5 software.
DISCUSSION
Nephrotoxicity leads to high mortality in cisplatin-treated
patients with cancer, therefore identification of preventive agents
for cisplatin-induced AKI is needed for clinical treatments.
Here, we identified a novel TCM monomer, protocatechuic
aldehyde, that protects against cisplatin-induced injury both
in vivo and in vitro via inhibiting Nox-mediated oxidative stress,
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renal inflammation, and programmed cell death of renal tubular
epithelial cells.
Protocatechuic aldehyde is a phenolic acid compound isolated
from several types of Chinese herbs, including roots of
miltiorrhiza, leaves of Stenolomachusanum (L.) Ching and Ilex
chinensis Sims (Li et al., 2012). In several animal models,
including cerebral ischemia model (Guo et al., 2016) and
experimental model of sepsis (Xu et al., 2012). PA has shown
pharmacological effects on inflammation and oxidative stress,
which are highly correlated with pathogenesis of cisplatin
nephropathy (Gao et al., 2011; Wei et al., 2013). For example, PA
alleviated cerebral ischemia-reperfusion-induced oxidative injury
via activating protein kinase Cε/Nrf2/HO-1 pathway (Guo et al.,
2016). In addition, treatment of PA suppressed TNF-α-induced
NF-κB phosphorylation and HMGB1 expression, attenuating
inflammatory response in RAW264.7 cells (Xu et al., 2012). PA
was also reported to reduce oxidative stress in sh-sy5y cells by
targeting Dj-1. However, whether PA prevents cisplatin-induced
AKI and the underlying mechanisms are still unknown.
In the current study, we found PA inhibited cisplatin-induced
decline of renal function, renal damage, cell death and apoptosis,
and inflammatory response in a dosage-dependent manner.
Interestingly, accumulating evidence shows that PA possesses
anti-cancer property by targeting cyclin D1-regulated cell cycle of
tumor cells (Jeong and Lee, 2013; Choi et al., 2014). Here, we used
three solid tumor cells lines, SMCC-7721, BEL-7402, and U87, to
test the effect of PA on tumor cell viability. We found PA failed to
reinforce the tumor suppressive effect of cisplatin. However, data
show that PA gently promoted anti-tumor activity of cisplatin in
U87 cell lines 24 h after cisplatin incubation. PA didn’t reduce
anti-tumor effects of cisplatin when protected against cisplatin
nephropathy, indicating PA-based therapy for cisplatin-induced
nephrotoxicity in cancer patients may be effective and promising.
Our results also show that PA significantly attenuated
oxidative stress by reducing ROS production in cisplatin-
challenged tubular epithelial cells and kidney tissues. This may
be one of the most critical mechanisms by which PA attenuates
cisplatin nephropathy. To date, evidence has shown that
oxidative stress plays critical roles in pathogenesis of cisplatin-
induced nephrotoxicity (Humanes et al., 2012). Multiple sources
for ROS in cells have been identified, including mitochondria,
xanthine oxidase, cytochrome P-450, and uncoupled nitric
oxide synthase (Humanes et al., 2012). NAPDH oxidases, a
set of membrane-associated proteins using NADPH to transfer
electrons across biological membranes and therefore generating
ROS, are regarded as one of key sources for ROS in the kidney
(Schreck and O’Connor, 2011). The Nox family consists of
seven members (Noxs 1–5, Duox1 and 2). Nox2 and Nox4 are
highly expressed within the kidney and Nox4 is known as the
predominant form, which plays important roles in renal oxidative
stress and kidney injury (Gill and Wilcox, 2006; Sedeek et al.,
2013; Kim et al., 2016; Oh et al., 2016). Our data show that
lentivirus-mediated knockdown of Nox4 in vivo significantly
attenuated cisplatin nephropathy. In the present study, both
in vivo and in vitro studies show that PA blocked cisplatin-
induced ROS generation, which was evidenced by results of GSH
assay, MDA assay, and ROS assay. Of note, cisplatin significantly
increased protein levels of Nox4 both in cisplatin-challenged
HK2 cells and cisplatin nephropathy, which was largely blocked
by PA treatment. More importantly, in vitro data indicated
that silencing Nox4, partly blocked the inhibitory effects of PA
on cisplatin-upregulated levels of KIM1, cleaved-caspase-3 and
production of inflammatory factors. This demonstrates that Nox4
may be the primary target in mediating the anti-oxidative stress
and protective role of PA in cisplatin-induced nephrotoxicity.
Additionally, it is noteworthy that Nox2 was significantly induced
by cisplatin, but suppressed by PA treatment, both in vivo and
in vitro; however, results generated from cisplatin-stimulated
Nox2 knockdown HK2 cells showed the less important role of
Nox2 in mediating the effects of PA compared with Nox4, as a
critical enzyme in the injury of kidney and other organs, (Gill and
Wilcox, 2006). Whether Nox2 is involved in PA treatment needs
to be further validated.
We also found that PA diminished cisplatin-induced
programmed cell death, especially necroptosis. As the best
characterized regulated necrosis, necroptosis is known to
play a critical role in cisplatin-induced AKI (Xu et al., 2015;
Linkermann, 2016). Administration of Nec-1, an inhibitor for
necroptosis, alleviated acute kidney injury induced by cisplatin
(Tristão et al., 2012), cyclosporin A (Ouyang et al., 2012), and
ischemia-reperfusion injury (Zhang et al., 2013). Emerging
evidence shows that RIP1, RIP3, and downstream MLKL serve
as predominant regulators in necroptosis while genetic deletion
or pharmalogical inhibition of these key genes significantly
reduced cisplatin-induced AKI (Linkermann et al., 2013, 2014;
Xu et al., 2015). Compared with apoptosis, necroptosis plays
more pivotal roles in the induction of inflammatory responses.
Cell membrane collapse induces the release of damage-associated
molecular patterns (DAMPs) including high-mobility group
box 1 (HMGB1), heat-shock proteins, uric acid, and IL-33,
which may interact with receptors (such as Toll-like receptors)
and initiate downstream signaling pathways to enhance renal
inflammation in a positive-feedback loop (Scaffidi et al., 2002;
Vilaysane et al., 2010; He et al., 2011). However, the mechanisms
by which PA blocks necroptosis is still to be determined. PA may
direct target key mediators in necroptosis-regulated pathways or
through indirect mechanisms in which Nox-dependent oxidative
stressare invovled.
Collectively, as shown in Figure 11 our study demonstrated
that PA substantially alleviated the decline of renal function and
renal damage while preventing renal oxidative stress, necroptosis,
and consequent inflammatory response. This may be correlated
with the inhibitory effect of PA on Nox4. Considering the finding
that PA significantly protects against cisplatin-induced acute
kidney injury without compromising the anti-cancer properties
of cisplatin, it should be further explored as a preventive agent
for cisplatin-treated cancer patients.
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